Ident. | Authors (with country if any) | Title |
---|
000299 (2011) |
Richard Camicioli [Canada] | Metabotropic glutamate receptors—mGluR5—new kid on the dissecting block? |
000429 (2011) |
Christopher Barnum [États-Unis] ; Malu G. Tansey [États-Unis] | Do microglial glucocorticoid receptors protect against loss of dopaminergic neurons in Parkinson's disease? |
000906 (2010) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations |
000D85 (2009) |
Maria Stamelou [Allemagne] ; Andreas Matusch [Allemagne] ; David Elmenhorst [Allemagne] ; René Hurlemann [Allemagne] ; Karla M. Eggert [Allemagne] ; Karl Zilles [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Günter U. Höglinger [Allemagne] ; Andreas Bauer [Allemagne] | Nigrostriatal upregulation of 5‐HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy |
001B38 (2007) |
Kjell Fuxe [Suède] ; Daniel Marcellino [Suède] ; Susanna Genedani [Italie] ; Luigi Agnati [Italie] | Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson's disease |
001B90 (2006) |
Christoph Scherfler [Royaume-Uni] ; Naheed L. Khan [Royaume-Uni] ; Nicola Pavese [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] ; David J. Brooks [Royaume-Uni] ; Paola P. Piccini [Royaume-Uni] | Upregulation of dopamine D2 receptors in dopaminergic drug‐naive patients with parkin gene mutations |
001F37 (2006) |
Stefanie Klaffke [Allemagne] ; Andrea A. Kuhn [Allemagne] ; Michail Plotkin [Allemagne] ; Holger Amthauer [Allemagne] ; Daniel Harnack [Allemagne] ; Roland Felix [Allemagne] ; Andreas Kupsch [Allemagne] | Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration |
002050 (2006) |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors |
002660 (2004) |
Valtteri Kaasinen [Finlande] ; Sargo Aalto [Finlande] ; Kjell N Gren [Finlande] ; Juha O. Rinne [Finlande] | Insular dopamine D2 receptors and novelty seeking personality in Parkinson's disease |
002A90 (2003) |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa‐induced motor complications |
002B71 (2002) |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni] | Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
002C97 (2002) |
Marie-Paule Muriel [France] ; Gaël Orieux [France] ; Etienne C. Hirsch [France] | Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats |
002E36 (2002) |
Joanne E. Nash [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned rat |
002F48 (2001) |
Marie-Paule Muriel [France] ; Yves Agid [France] ; Etienne Hirsch [France] | Plasticity of afferent fibers to striatal neurons bearing D1 dopamine receptors in Parkinson's disease |
003247 (2000) |
Rae R. Matsumoto [États-Unis] ; Daniel D. Truong [États-Unis] ; Kevin D. Nguyen [États-Unis] ; A. Terri Dang [États-Unis] ; Tin T. Hoang [États-Unis] ; Phi Q. Vo [États-Unis] ; Paola Sandroni [États-Unis] | Involvement of GABAA receptors in myoclonus |
003493 (1999) |
Piero Barbanti ; Giovanni Fabbrini ; Alberto Ricci ; Rosanna Cerbo ; Elena Bronzetti ; Brunella Caronti ; Caterina Calderaro ; Laura Felici ; Fabrizio Stocchi [Italie] ; Giuseppe Meco ; Francesco Amenta [Italie] ; Gian Luigi Lenzi | Increased expression of dopamine receptors on lymphocytes in Parkinson's disease |
003943 (1997) |
Angelo Antonini [Suisse] ; Johannes Schwarz [Suisse] ; Wolfgang H. Oertel [Suisse] ; Oliver Pogarell [Suisse] ; Leenders [Suisse, Allemagne] | Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride |
003B35 (1996) |
Jauss [Allemagne] ; P. Krack [Allemagne] ; M. Franz [Allemagne] ; R. Klett [Allemagne] ; R. Bauer [Allemagne] ; B. Gallhofer [Allemagne] ; W. Dorndorf [Allemagne] | Imaging of dopamine receptors with [123I]iodobenzamide single‐photon emission–computed tomography in neuroleptic malignant syndrome |
004059 (1993) |
Kostic [Serbie] ; Zorica Marinkovic [Serbie] ; Sasa Filipovic [Serbie] ; Dragana Momcilovic [Serbie] | Function of dopamine receptors in young‐onset parkinson's disease: Prolactin response |
004064 (1993) |
Baltazar Gomez-Mancilla [Canada, Suisse] ; René Boucher [Canada, Suisse] ; Céline Gagnon [Canada, Suisse] ; Thérèse Di Paolo [Canada, Suisse] ; Rudolf Markstein [Canada, Suisse] ; Bédard [Canada, Suisse] | Effect of adding the D1 agonist CY 208–243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
004067 (1993) |
Strange [Royaume-Uni] | Dopamine receptors in the basal ganglia: Relevance to parkinson's disease |